OncoMatch/Bile Duct Cancer (Cholangiocarcinoma)/HER2 (ERBB2)
Bile Duct Cancer (Cholangiocarcinoma)HER2 (ERBB2) Clinical Trials
HER2 amplification or overexpression occurs in approximately 5–10% of biliary tract cancers and is now an actionable therapeutic target. Zanidatamab, a bispecific HER2 antibody, is FDA accelerated-approved for previously treated unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Trials investigate zanidatamab combinations, trastuzumab deruxtecan (T-DXd), and other HER2-directed agents with checkpoint inhibitors across amplification levels.
Top recruiting HER2 (ERBB2) Bile Duct Cancer (Cholangiocarcinoma) trials
Ranked by phase and US site count.
See all trials matched to your profile →Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
AstraZeneca
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Jazz Pharmaceuticals
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Tata Memorial Centre
Study for AZD4360 in Participants With Advanced Solid Tumours
AstraZeneca
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.